Mike Zaman's  Instablog

Mike Zaman
Send Message
  • Covidien (NYSE:COV) To Sell Confluent Surgical Product Line To Integra LifeSciences (Nasdaq:IART) 0 comments
    Oct 28, 2013 7:41 PM | about stocks: IART, MDT


    https://staticseekingalpha.a.ssl.fastly.net/uploads/2013/10/28/saupload_cov.jpg Covidien plc (NYSE:COV)

    https://staticseekingalpha.a.ssl.fastly.net/uploads/2013/10/28/saupload_iart1.jpg Integra LifeSciences Holdings Corp. (Nasdaq:IART)

    COV reported that it has entered into a definitive agreement with IART to sell its Confluent Surgical product line.

    Under the terms of the agreement, COV will receive an initial cash payment of $235 million from IART upon the closing of the transaction. Additionally, COV may receive up to $30 million, contingent upon the achievement of certain performance measures related to the transition of the Confluent Surgical business to IART.


    COV is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. COV manufactures, distributes and services a diverse range of industry-leading products in medical devices and supplies.

    More about Integra LifeSciences Holdings Corp. (Nasdaq:IART) at www.covidien.com


    Read full disclaimer at www.mikezaman.com/disclaimer

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Stocks: IART, MDT
Back To Mike Zaman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.